Login to Your Account



Japan's regenerative medicine path opens doors to early stage work

By Nuala Moran
Staff Writer

Wednesday, May 28, 2014

LONDON – An expedited approval system for regenerative medicines coming into effect in Japan in November will provide a possible route for cell therapy companies from around the world to get conditional approval and reimbursement on the basis of phase I/II data confirming safety and indicating a product is likely to be effective.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription